X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (811) 811
Book Review (207) 207
Publication (30) 30
Conference Proceeding (5) 5
Book Chapter (3) 3
Dissertation (3) 3
Magazine Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
empagliflozin (787) 787
index medicus (433) 433
humans (316) 316
diabetes (315) 315
type 2 diabetes (291) 291
endocrinology & metabolism (257) 257
glucose (244) 244
diabetes mellitus, type 2 - drug therapy (239) 239
dapagliflozin (236) 236
diabetes mellitus (213) 213
canagliflozin (207) 207
double-blind (192) 192
hypoglycemic agents - therapeutic use (160) 160
sodium-glucose transporter 2 - antagonists & inhibitors (154) 154
sglt2 inhibitor (152) 152
male (146) 146
sodium (144) 144
dextrose (137) 137
metformin (133) 133
glucosides - therapeutic use (130) 130
safety (129) 129
sglt2 inhibitors (129) 129
cardiac & cardiovascular systems (127) 127
pharmacology & pharmacy (126) 126
benzhydryl compounds - therapeutic use (125) 125
type 2 diabetes mellitus (123) 123
female (119) 119
heart failure (119) 119
middle aged (113) 113
clinical trials (108) 108
mortality (107) 107
analysis (102) 102
blood pressure (101) 101
risk factors (95) 95
glycemic control (94) 94
mellitus (91) 91
risk (91) 91
treatment outcome (90) 90
hypoglycemic agents - adverse effects (89) 89
type-2 diabetes-mellitus (89) 89
aged (88) 88
cardiovascular diseases (86) 86
efficacy (85) 85
hypoglycemic agents (84) 84
insulin (84) 84
cardiovascular disease (82) 82
care and treatment (82) 82
outcomes (82) 82
adult (81) 81
disease (81) 81
internal medicine (81) 81
add-on (78) 78
blood-pressure (77) 77
diabetes mellitus, type 2 - complications (77) 77
heart-failure (76) 76
medicine & public health (74) 74
medicine, general & internal (73) 73
diabetes mellitus, type 2 - blood (72) 72
glucosides - adverse effects (72) 72
cardiovascular outcomes (71) 71
patients (70) 70
animals (69) 69
benzhydryl compounds - adverse effects (69) 69
drug therapy (67) 67
body weight (66) 66
inhibitors (66) 66
hyperglycemia (64) 64
sodium-glucose transporter 2 - metabolism (63) 63
sglt2 (61) 61
diabetes therapy (60) 60
blood glucose - drug effects (55) 55
cardiology (55) 55
kidney diseases (55) 55
hypoglycemic agents - administration & dosage (54) 54
glucosides - pharmacology (53) 53
benzhydryl compounds - pharmacology (52) 52
liraglutide (52) 52
glucosides - administration & dosage (51) 51
heart diseases (51) 51
hypoglycemic agents - pharmacology (50) 50
review (50) 50
double-blind method (49) 49
add-on therapy (48) 48
blood glucose - metabolism (48) 48
hypertension (48) 48
hypoglycemia (48) 48
abridged index medicus (47) 47
benzhydryl compounds - administration & dosage (47) 47
glucose transporter (46) 46
inadequate glycemic control (46) 46
pharmacokinetics (46) 46
medical research (44) 44
kidney-disease (43) 43
peripheral vascular disease (43) 43
research (43) 43
studies (43) 43
type-2 (43) 43
kidneys (42) 42
sitagliptin (42) 42
blood pressure - drug effects (41) 41
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (764) 764
German (21) 21
Spanish (10) 10
Czech (9) 9
French (7) 7
Russian (3) 3
Korean (2) 2
Japanese (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


DIABETES CARE, ISSN 0149-5992, 05/2014, Volume 37, Issue 5, pp. 1480 - 1483
OBJECTIVEAdjunctive-to-insulin therapy with sodium-glucose cotransporter 2 (SGLT2) inhibition may improve glycemic control in type 1 diabetes (T1D).RESEARCH... 
INSULIN | ENDOCRINOLOGY & METABOLISM | KETOACIDOSIS | EMPAGLIFLOZIN | SGLT-2 INHIBITOR
Journal Article
NATURE REVIEWS NEPHROLOGY, ISSN 1759-5061, 12/2017, Volume 13, Issue 12, pp. 728 - 729
New data from the LEADER trial show that the glucagon-like peptide 1 receptor agonist liraglutide protects against diabetic nephropathy in patients with type 2... 
UROLOGY & NEPHROLOGY | OUTCOMES | LIRAGLUTIDE | KIDNEY | EMPAGLIFLOZIN
Journal Article
AMERICAN JOURNAL OF MEDICINE, ISSN 0002-9343, 06/2017, Volume 130, Issue 6, pp. S1 - S3
Journal Article
NATURE REVIEWS NEPHROLOGY, ISSN 1759-5061, 02/2018, Volume 14, Issue 2, pp. 78 - 78
2017 saw the emergence of a new era in renoprotective medicine for diabetic kidney disease with reports of promising renal outcomes with the sodium-glucose... 
UROLOGY & NEPHROLOGY | OUTCOMES | TYPE-2 | EMPAGLIFLOZIN
Journal Article
Molecular and Cellular Endocrinology, ISSN 0303-7207, 12/2019, Volume 498, pp. 110539 - 110539
To evaluate the pleiotropic effects of empagliflozin in the liver through lipogenesis, beta-oxidation, and endoplasmic reticulum stress pathways. Male C57Bl/6... 
Empagliflozin | Hepatic steatosis | Lipogenesis | Endoplasmic reticulum stress | Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 08/2016, Volume 134, Issue 8, pp. 571 - 573
Journal Article
The Lancet Diabetes & Endocrinology, ISSN 2213-8587, 01/2019, Volume 7, Issue 1, pp. 4 - 5
Journal Article
European Journal of Heart Failure, ISSN 1388-9842, 07/2019, Volume 21, Issue 7, pp. 874 - 876
Journal Article
European Heart Journal, ISSN 0195-668X, 06/2018, Volume 39, Issue 24, pp. 2221 - 2225
Journal Article
AMERICAN JOURNAL OF CARDIOLOGY, ISSN 0002-9149, 07/2017, Volume 120, Issue 1, pp. S1 - S3
Journal Article
Circulation, ISSN 0009-7322, 06/2019, Volume 139, Issue 25, pp. 2831 - 2834
Journal Article
AMERICAN JOURNAL OF KIDNEY DISEASES, ISSN 0272-6386, 09/2019, Volume 74, Issue 3, pp. 328 - 337
Rationale & Objective: Hyperglycemia exacerbates the progression of chronic kidney disease (CKD), but most glucose-lowering therapies do not address... 
DAPAGLIFLOZIN | EFFICACY | SGLT2 INHIBITORS | UROLOGY & NEPHROLOGY | RISK | PHARMACODYNAMICS | CHRONIC KIDNEY-DISEASE | BLOOD-GLUCOSE CONTROL | EMPAGLIFLOZIN
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2019, Volume 380, Issue 4, pp. 347 - 357
In a randomized trial of patients with type 2 diabetes, treatment with dapagliflozin, an SGLT2 inhibitor that promotes glucosuria, did not result in a higher... 
2013 ACCF/AHA GUIDELINE | MEDICINE, GENERAL & INTERNAL | SELECTIVE SGLT2 INHIBITOR | MANAGEMENT | HEART-FAILURE OUTCOMES | DISEASE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | KIDNEY | EMPAGLIFLOZIN | SOCIETY | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Type 2 diabetes | Safety and security measures | Dapagliflozin | Dosage and administration | Drug therapy | Cardiovascular diseases | Risk factors | Heart failure | Myocardial infarction | Cerebral infarction | End-stage renal disease | Heart attacks | Mortality | Diabetes mellitus | Cardiovascular disease | FDA approval | Patients | Glomerular filtration rate | Heart rate | Ischemia | Sodium | Arteriosclerosis | Ketoacidosis | Death | Diabetes | Kidney diseases | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 10/2018, Volume 72, Issue 15, pp. 1845 - 1855
Patients with type 2 diabetes mellitus have an increased risk for the development of cardiac and other vascular events, heart failure (HF), and decline in... 
heart failure | renal function | diabetes | SGLT2 inhibitor | KIDNEY-DISEASE | CARDIAC & CARDIOVASCULAR SYSTEMS | DAPAGLIFLOZIN | SGLT2 INHIBITORS | HEART-FAILURE | RISK | DEATH | ESTABLISHED CARDIOVASCULAR-DISEASE | PHARMACOKINETICS | OUTCOMES | EMPAGLIFLOZIN
Journal Article